Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases. Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemia-reperfusion injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release bradykinin via an EET-mediated STAT3 signaling pathway to inhibit elicit tolerance to ischemia. Summary: Inhibition of sEH has been shown to improve several aspects of cardiovascular disease, including inflammation, hypertension, cardiac hypertrophy and atherosclerosis. For this reason, sEHIs are a promising new pharmaceutical for the treatment of cardiovascular disease.
Current Vascular Pharmacology 02/2012; DOI:10.2174/15701611130113 · 2.91 Impact Factor